MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Upgraded by Zacks Research

MoonLake Immunotherapeutics (NASDAQ:MLTX) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

MLTX has been the subject of several other research reports. Citigroup lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research report on Wednesday, October 29th. Royal Bank Of Canada boosted their price objective on MoonLake Immunotherapeutics from $10.00 to $12.00 and gave the company a “sector perform” rating in a report on Friday, February 20th. BTIG Research lifted their target price on MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, February 3rd. Finally, The Goldman Sachs Group cut shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and boosted their price objective for the company from $8.00 to $10.00 in a research report on Wednesday, January 14th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $27.15.

MoonLake Immunotherapeutics Price Performance

Shares of MoonLake Immunotherapeutics stock opened at $18.22 on Tuesday. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -5.49 and a beta of 1.21. The stock has a 50 day moving average price of $15.47 and a 200-day moving average price of $23.57. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.97) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.97). During the same quarter in the prior year, the firm posted ($0.72) EPS. Equities analysts expect that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Insiders Place Their Bets

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 72,908 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total transaction of $1,052,062.44. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Da Silva Jorge Santos sold 70,000 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $14.49, for a total value of $1,014,300.00. Following the completion of the transaction, the chief executive officer directly owned 2,878,577 shares of the company’s stock, valued at approximately $41,710,580.73. The trade was a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 402,908 shares of company stock valued at $5,987,162. 12.02% of the stock is owned by company insiders.

Institutional Trading of MoonLake Immunotherapeutics

Several hedge funds have recently modified their holdings of MLTX. Kestra Advisory Services LLC purchased a new position in shares of MoonLake Immunotherapeutics in the 4th quarter worth approximately $26,000. FNY Investment Advisers LLC purchased a new stake in MoonLake Immunotherapeutics during the third quarter valued at approximately $28,000. Bank of America Corp DE boosted its stake in MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after acquiring an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after purchasing an additional 3,166 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of MoonLake Immunotherapeutics by 45.4% during the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after purchasing an additional 1,069 shares during the last quarter. 93.85% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Multiple analyst price-target increases and buy ratings lifted sentiment — BTIG raised its target to $30 (buy) and Needham to $25 (buy), both implying meaningful upside from current levels. BTIG & Needham coverage (Benzinga)
• Positive Sentiment: Coverage noting a higher price target (reported as an 11.25% increase to $22.30) also supports near-term upside and analyst optimism. Price target increase report
• Positive Sentiment: New clinical data coverage described as “turning the tables” on sonelokimab, suggesting fresh positive data that could improve the drug’s commercial and regulatory outlook across inflammatory indications. MoonLake turns the tables on sonelokimab
• Neutral Sentiment: Analyst model update: Lifesci Capital narrowed its Q4 2025 EPS loss estimate (from ($1.14) to ($0.90)), reflecting slightly improved expectations but the company still projects a meaningful loss for the year. This reduces downside risk but doesn’t yet change profitability outlook materially.
• Negative Sentiment: One analyst note downgraded MLTX from Strong Buy to Buy after a mixed Phase 3 outcome (VELA‑2 missed its primary endpoint). The note highlights execution and regulatory uncertainty despite an FDA Type B meeting that left open a BLA path — this introduces near-term clinical and approval risk. Seeking Alpha downgrade coverage

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.